ICI’s Nolvadex

Executive Summary

Tamoxifen for the prevention of breast cancer is well tolerated in women at high risk for developing breast cancer, T.J. Powels, MD, Royal Marsden Hospital concluded in a presentation at the May 22 meeting of the American Society of Clinical Oncology. Because tamoxifen has demonstrated low toxicity, high compliance, and a lipid lowering profile in the 200-women pilot trial, a 10,000-patient multicenter trial is beginning enrollment in the U.K. and should be completed in the next two years, Powles said. Results of the pilot trial will be presented at the June 29 meeting of FDA's Oncologic Drugs Advisory Committee.